Jeanette Winterling

Jeanette Winterling

Affiliated to Research | Docent
Visiting address: Alfred Nobels Allé 23, 14183 Huddinge
Postal address: H1 Neurobiologi, vårdvetenskap och samhälle, H1 Omvårdnad, 171 77 Stockholm
Part of:

About me

  • I work as a head of the Psychooncology unit for adult cancer patients and the survivorship unit for adults that had cancer as a child at the
    Comprehensive Cancer Centre (Theme Cancer) at the Karolinska Comprehensiv Cancer Centre at Karolinska University Hospital in Stockholm.

    As a researcher I am conected to Yvonne Wengströms research group at Karolinska Institutet.

    Education:

    Registred Nurse 1997
    Basic education in Psychoterapy 2000
    Magister in Caring Science 2002
    PhD in Caring Science 2007

    Associate professor in Caring Sience 2023

Research

  • My research has consistently focused on psychosocial aspects of patients and relatives with cancer.

    I finished my PhD in 2007 at Uppsala University with the thesis "Hope and Despair - Philosophy of life, expectations and optimism in cancer patient and their spouses”. The thesis involved life situation, philosophy of life, optimism and bereavement in patients with gastrointestinal cancer in a palliative phase, and their spouses, as well as on cancer patients' expectations on the time coming after they finished a curative cancer treatment. I did a postdoc in the /Fex-Can r/esearch project which included to examine different aspects of children, teens and young adults' situation during and after cancer, such as life situation, school situation, sexuality and fertility.


    I am involved in several resarch project and these are the project I´m leading or being one of the leaders in: 

    • The MyCode project - It consists of several subprojects with the aim to provide AYAs aged 16-30 years of age close to diagnosis and under their cancer treatment with support and tools to better cope with their cancer journey. One subproject is about adapting, implementing and evaluating a supprt moddel for AYAs, including a team young and the PRISM intervention at Karolinska and Sahlgrenska Comprehensive cancer centre. 
    • The aCent research project - It is about developing, implementing and evaluation a model for person-centred care for patients and family caregivers in the context of allogenic stem cell transplantation.
    • The Donor research project - It is about investigationd the psychological well being of donors in allogenic stem cell transplantation.
    • The Frailty project -  It is about investigating frailty in the context of lung cancer with the sceening tool of frailty called the Edmonton Frail Scale.

Teaching

  • I am course coordinator for the course Rehabilitation within cancer care, 7.5 hp at Karolinska Institutet and are involved in other courses at Karolinska as well as other Universities. 

Articles

All other publications

Grants

  • Swedish Research Council
    1 January 2023 - 31 December 2026
    Background: The age standardised rate of yearly new cancer cases is 190/100 000 globally, by WHO. 30-40% of these will develop depression. There is currently no specific antidepressant treatment regime implemented in the cancer population. This is in spite of the specific needs given by concurrent cancer treatments, limited quality of life from the cancer per se and the often limited life expectancy from a cancer disease. A single dose of psilocybin combined with 3 hours of psychological support has shown rapid (within days) and long term (months or years) antidepressant effect in several small studies in different cancer populations. Large, well designed RCTs are still lacking, as is response predictors for treatment guidance. I am PI of the first RCT of psilocybin treament of depression in Sweden, expected to end randomisation in june 2022. CAPSI: 100 patients with cancer and depression will be randomised to psilocybin or active placebo (2:1) at 4 different regions in Sweden during 2024-2025. Primary end point is depressive symptoms 6 weeks post dose and follw up is 6 months. All subjects will undergo EEG and blood sampling, a subsample (n=50) will also undergo MEG and fMRI, and 25 of them also PET, in order to develop a EEG proxy response signature. Together with markers in blood we will develop a predictor model for psilocybin treatment response. All data will be used to motivate a phase three study with the same PICO and further development of the response markers.

Employments

  • Affiliated to Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 2024-2027

Degrees and Education

  • Docent, Nursing, Karolinska Institutet, 2023

News from KI

Events from KI